3M CO Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO William M. Brown; PEO total compensation $21.01M; PEO compensation actually paid $35.74M; Other NEO average total compensation $6.19M.
- 2024-12-31: PEO William M. Brown; Other NEO average total compensation $7.01M.
- 2023-12-31: PEO Michael F. Roman; PEO total compensation $16.42M; PEO compensation actually paid $15.62M; Other NEO average total compensation $11.19M.
- 2022-12-31: PEO Michael F. Roman; PEO total compensation $14.03M; PEO compensation actually paid $152.48K; Other NEO average total compensation $5.32M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | William M. Brown | $21.01M | $35.74M | $6.19M | $11.01M | $132.00 | $173.00 | $3.25B | Organic Sales Growth $0.02 | 2026-03-25 |
| 2024-12-31 | William M. Brown | $7.01M | $5.57M | $104.00 | $150.00 | $4.17B | $0.02 | 2026-03-25 | ||
| 2023-12-31 | Michael F. Roman | $16.42M | $15.62M | $11.19M | $11.58M | $71.00 | $131.00 | -$7.00B | -$0.01 | 2026-03-25 |
| 2022-12-31 | Michael F. Roman | $14.03M | $152.48K | $5.32M | $1.85M | $74.00 | $113.00 | $5.78B | $0.01 | 2026-03-25 |
| 2021-12-31 | Michael F. Roman | $18.20M | $18.44M | $5.53M | $3.55M | $105.00 | $121.00 | $5.92B | $0.09 | 2026-03-25 |
| 2024-12-31 | $7.01M | $5.57M | $107.00 | $165.00 | $4.17B | Organic Sales Growth $0.02 | 2025-03-26 | |||
| 2023-12-31 | $16.42M | $15.62M | $11.19M | $11.58M | $73.00 | $144.00 | -$7.00B | -$0.03 | 2025-03-26 | |
| 2022-12-31 | $14.03M | $152.48K | $5.32M | $1.85M | $76.00 | $124.00 | $5.78B | $0.01 | 2025-03-26 | |
| 2021-12-31 | $18.20M | $18.44M | $5.53M | $3.55M | $108.00 | $133.00 | $5.92B | $0.09 | 2025-03-26 | |
| 2020-12-31 | $20.70M | $15.70M | $5.81M | $2.34M | $103.00 | $110.00 | $5.38B | -$0.02 | 2025-03-26 | |
| 2023-12-31 | Michael F. Roman | $16.42M | $15.62M | $11.19M | $11.58M | $73.36 | $143.60 | -$7.00B | Organic Sales Growth -$0.03 | 2024-03-27 |
| 2022-12-31 | $14.03M | $152.48K | $5.32M | $1.85M | $75.89 | $123.60 | $5.78B | $0.01 | 2024-03-27 | |
| 2021-12-31 | $18.20M | $18.44M | $5.53M | $3.55M | $107.80 | $132.71 | $5.92B | $0.09 | 2024-03-27 | |
| 2020-12-31 | $20.70M | $15.70M | $5.81M | $2.34M | $102.79 | $109.72 | $5.38B | -$0.02 | 2024-03-27 | |
| 2022-12-31 | Michael F. Roman | $14.03M | $152.48K | $5.33M | $1.85M | $75.89 | $123.60 | $5.78B | Organic Sales Growth $1.20 | 2023-03-22 |
| 2021-12-31 | Michael F. Roman | $18.20M | $18.44M | $5.52M | $3.55M | $107.80 | $132.71 | $5.92B | $8.80 | 2023-03-22 |
| 2020-12-31 | Michael F. Roman | $20.70M | $15.70M | $5.81M | $2.34M | $102.79 | $109.72 | $5.38B | -$1.70 | 2023-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STRYKER CORP (SYK) | United States | $103.511B | 32.39 |
| BOSTON SCIENTIFIC CORP (BSX) | United States | $64.781B | 17.29 |
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |